Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 5/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | RECQL | P46063 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ATP1A1 | P05023 | 3/20 | 0.56 |
| ▸ | ATP1B1 | P05026 | 3/20 | 0.56 |
| ▸ | ATP1A3 | P13637 | 3/20 | 0.56 |
| ▸ | ATP1B2 | P14415 | 3/20 | 0.56 |
| ▸ | ATP1A2 | P50993 | 3/20 | 0.56 |
| ▸ | ATP1B3 | P54709 | 3/20 | 0.56 |
| ▸ | FXYD2 | P54710 | 3/20 | 0.56 |
| ▸ | ATP1A4 | Q13733 | 3/20 | 0.56 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5569925 | 0.86 | ABCG2 (0.68) | TERTKDM4EMAPTPKMRECQL | |
| SCHEMBL31438664 | 0.86 | ABCG2 (0.68) | TERTKDM4EMAPTPKMRECQL | |
| SCHEMBL7375249 | 0.86 | CA12 (0.56) | TERTKDM4EMAPTPKMRECQL | |
| SCHEMBL6616091 | 0.84 | TERT (1.00) | TERTKDM4EMAPTPKMRECQL | |
| SCHEMBL8513483 | 0.82 | TERT (0.68) | TERTKDM4EMAPTPKMRECQL | |
| SCHEMBL31290900 | 0.79 | GAA (0.58) | TERTKDM4EMAPTPKMRECQL | |
| SCHEMBL22266149 | 0.79 | GAA (0.58) | TERTKDM4EMAPTPKMRECQL | |
| SCHEMBL8511950 | 0.79 | APP (0.74) | TERTKDM4EMAPTPKMRECQL | |
| SCHEMBL21647180 | 0.79 | TERT (0.62) | TERTKDM4EMAPTPKMRECQL | |
| SCHEMBL9612317 | 0.77 | TERT (0.75) | TERTKDM4EMAPTPKMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2579870-A2 | TRKB AGONISTS AND METHODS OF USE | Emory University (US) | 2013-04-17 | — | — | EP | claimed |
| US-20130040947-A1 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2013-02-14 | — | — | US | claimed |
| WO-2011156479-A9 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2012-05-31 | — | — | WO | claimed |
| WO-2011156479-A2 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2011-12-15 | — | — | WO | claimed |
| EP-2579870-B1 | TRKB AGONISTS AND METHODS OF USE | UNIV EMORY (US) | 2018-02-14 | — | — | EP | disclosed |
| EP-2579870-B1 | TRKB AGONISTS AND METHODS OF USE | UNIV EMORY (US) | 2018-02-14 | — | — | EP | disclosed |
| US-9504674-B2 | TrkB agonists and methods of use | EMORY UNIVERSITY (US) | 2016-11-29 | — | — | US | disclosed |
| US-9504674-B2 | TrkB agonists and methods of use | EMORY UNIVERSITY (US) | 2016-11-29 | — | — | US | disclosed |
| US-9504674-B2 | TrkB agonists and methods of use | EMORY UNIVERSITY (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150174107-A1 | TRKB AGONISTS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-25 | — | — | US | disclosed |
| US-20150174107-A1 | TRKB AGONISTS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-25 | — | — | US | disclosed |
| US-20150174107-A1 | TRKB AGONISTS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-25 | — | — | US | disclosed |
| EP-2579870-A2 | TRKB AGONISTS AND METHODS OF USE | Emory University (US) | 2013-04-17 | — | — | EP | disclosed |
| US-20130040947-A1 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130040947-A1 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130040947-A1 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2013-02-14 | — | — | US | disclosed |
| WO-2011156479-A9 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2012-05-31 | — | — | WO | disclosed |
| WO-2011156479-A9 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2012-05-31 | — | — | WO | disclosed |
| WO-2011156479-A2 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011156479-A2 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040947-A1 | TRKB AGONISTS AND METHODS OF USE | NTRK2, BDNF, NTRK1 | TERT 2930/4885KDM4E 1353/4885MAPT 1145/4885 |
| US-20150174107-A1 | TRKB AGONISTS AND METHODS OF USE | NTRK2, BDNF, NTRK1 | TERT 2908/4885KDM4E 1150/4885MAPT 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.